MINZE-HEALTH
1.12.2022 15:01:43 CET | Business Wire | Press release
Minze Health announced today that White Fund, Capricorn Partners and PMV have jointly invested €3.9 million in the company to fund its further growth and product development roadmap.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005062/en/
Minze Diary, a novel and automated bladder diary enabling quicker and better treatment of LUTS. (Photo: Minze Diary)
Minze Health is a digital healthcare scale-up that enables better care for 2.3 billion people with Lower Urinary Tract Symptoms (LUTS). Most common symptoms are urinary incontinence, a weak urine stream due to an enlarged prostate, frequent voiding and night voiding. Urological complaints remain taboo subjects in today’s society, as a result of which people are often treated too late or not at all. Minze Health is committed to lowering this barrier by offering simple and accessible screening for patients and better and user-friendly diagnostic and remote monitoring tools for healthcare professionals.
White Fund, a private equity fund focused on MedTech, led the funding round and was joined by Capricorn Partners via their Capricorn Digital Growth Fund and by the Flemish investment company PMV.
Worldwide, 300 hospitals, urology practices and pelvic floor rehabilitation centers are already working with Minze’s digital health and Remote Patient Monitoring (RPM) solutions. The proceeds will be used to conduct more clinical studies in Europe and the US, to execute Minze’s product roadmap, as well as to invest in international B2B/B2C go to market strategies.
Philippe Stas, Executive Committee Member at White Fund: “We know that due to an aging population, the LUTS prevalence number will only increase. At the same time there is an enormous pressure on our healthcare system and costs are rising every year. Digital health and health at home can improve a patient's quality of life, while at the same time significantly saving on healthcare costs. We were impressed with the progress made by Minze in recent years and believe that the company plays an essential global role in the digitalization of urology healthcare.”
Katrin Geyskens, Partner at Capricorn Partners: “The combination of Minze’s hardware & software based on explainable AI makes Minze Health unique in the field of LUTS treatment. By generating unique datasets per patient, Minze enables personalized healthcare ranging from lifestyle advice to digital therapeutics. Capricorn Partners is excited to help Minze to support patients and healthcare providers in making better decisions in their daily life.”
Tine Bekaert, Senior Investment Manager at PMV: “Minze Health’s solutions to often unspoken social problems, represent enormous international potential. We are convinced that thanks to a unique combination of medical devices with low-threshold and comprehensive software diagnostics, patients around the world facing urology problems will find their way to this accessible form of home diagnostics. We therefore fully support Minze Health in this crucial phase of international expansion.”
Wilfried Woesthuis, CEO at Minze Health: “We are honored to have White Fund, Capricorn and PMV on board. Their trust in Minze helps us to achieve our mission: bring LUTS diagnostics, treatment and follow-up to the patient's home, thus making treatment more accessible. We aim to improve care for an underserved population of approx. 1.5 billion people with urinary problems, while keeping healthcare sustainable and affordable. The investment consortiums’ expertise, network and financial support will help us to realize this ultimate goal.”
For more information on White Fund, please visit www.whitefund.be
For more information on Capricorn Partners, please visit www.capricorn.be
For more information on PMV, please visit www.pmv.eu
For more information on Minze Health, please visit www.minzehealth.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 14:30:00 CEST | Press release
‘IAS Total TV’ unlocks show, genre and rating transparency measurement across Disney, NBCUniversal, Paramount and Prime Video, plus multiple opted-in publishers using Publica enabling advertisers to enhance brand suitability while increasing campaign outcomes Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to doub
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release
New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release
90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom